Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 16/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193583 | 0.85 | CHRM2 (0.57) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL4172759 | 0.81 | CHRM2 (0.55) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL4198454 | 0.74 | CHRM3 (0.51) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL3228444 | 0.73 | CHRM3 (0.52) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL3214839 | 0.73 | CHRM3 (0.52) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL3717717 | 0.73 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4198451 | 0.72 | CHRM3 (0.44) | CHRM3CHRM1CHRM2SMN1; SMN2NPC1 | |
| SCHEMBL14940262 | 0.71 | CHRM3 (0.64) | CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL20799603 | 0.70 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL16321021 | 0.70 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | claimed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM1 4/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.